BC Week In Review | Apr 15, 2013
Company News

Innovir management update

Innovir Laboratories Inc. (INVR), New York, N.Y.   Business: Cancer, Infectious diseases/AIDS   Hired: Francis O'Connell as CFO; he retains his position as VP of finance at VIMRx Pharmaceuticals Inc. but vacates his position of...
BC Week In Review | Apr 15, 2013
Company News

Innovir board of directors update

Innovir Laboratories Inc. (INVR), New York, N.Y.   Business: Cancer, Infectious diseases/AIDS   Appointed: Stanley Knowlton, president of Knowlton Brothers Inc. investment firm, and associate at Melhado Flynn & Associates, brokerage and investment firm  ...
BC Week In Review | Dec 8, 2008
Company News

VimRx, Columbia University deal

VMRX and Columbia will collaborate to develop disease-gene identification technologies through the company's new VIMRx Genomics Inc. subsidiary (New York, N.Y.). During the five-year collaboration, VimRx Genomics will provide $30 million to the Columbia Genome...
BC Week In Review | Jan 4, 2000
Company News

Nexell other research news

Researchers at NEXL's Innovir Laboratories Inc. subsidiary (Wilmington, Del.) and colleagues published in Nature Biotechnology that oligos containing EGS, but not control sequences, were effective in specifically downregulating target mRNA transcripts. They suggested the technology...
BC Week In Review | Aug 23, 1999
Company News

Nexell, Ribozyme deal

RZYM acquired all ribozyme-related intellectual property from NEXL's Innovir Laboratories Inc. subsidiary (Wilmington, Del.), including ribozyme motifs, target validation, diagnostics, and oligonucleotide technology. RZYM said the acquisition relates to the closing of Innovir's ribozyme-based research...
BC Week In Review | Oct 19, 1998
Company News

Innovir cancer, infectious diseases news

Innovir, a subsidiary of VimRx Pharmaceuticals Inc. (VMRX, Wilmington, Delaware), said it will close its New York operations and relocate to VMRX's headquarters. In May, Innovir announced an operating expense reduction plan and began closing...
BC Week In Review | Jul 27, 1998
Company News

Innovir cancer, infectious diseases news

INVR was served with a complaint in the U.S. Bankruptcy Court for the Southern District of New York by the Trustee for the liquidation of the business of the now defunct investment firm A. R....
BC Week In Review | May 26, 1998
Company News

Innovir cancer, infectious diseases news

INVR, a subsidiary of VimRx Pharmaceuticals Inc. (VMRX, Wilmington, Del.) said its oligozyme development program will be refocused on functional ribozyme selection (FRS) and related technologies based on the company’s external guide sequence (EGS) technology....
BC Week In Review | May 11, 1998
Company News

Stressgen management update

(SSB SAB, below) StressGen Biotechnologies Corp. (TSE:SSB), Victoria, B.C.   Business: Cancer, Gene/Cell therapy, Infectious diseases   Hired: Paul Leibowitz as VP of corporate development, formerly SVP of Innovir Laboratories Inc.   Resigned: Vincent Salvatori,...
BC Week In Review | Mar 30, 1998
Company News

Innovir other research news

INVR, a subsidiary of VimRx Pharmaceuticals Inc. (VMRX, Wilmington, Del.), reported development of the FRS technology, which identifies sites in messenger RNA molecules that can be cleaved by a ribozyme or External Guide Sequence oligonucleotide....
Items per page:
1 - 10 of 22
BC Week In Review | Apr 15, 2013
Company News

Innovir management update

Innovir Laboratories Inc. (INVR), New York, N.Y.   Business: Cancer, Infectious diseases/AIDS   Hired: Francis O'Connell as CFO; he retains his position as VP of finance at VIMRx Pharmaceuticals Inc. but vacates his position of...
BC Week In Review | Apr 15, 2013
Company News

Innovir board of directors update

Innovir Laboratories Inc. (INVR), New York, N.Y.   Business: Cancer, Infectious diseases/AIDS   Appointed: Stanley Knowlton, president of Knowlton Brothers Inc. investment firm, and associate at Melhado Flynn & Associates, brokerage and investment firm  ...
BC Week In Review | Dec 8, 2008
Company News

VimRx, Columbia University deal

VMRX and Columbia will collaborate to develop disease-gene identification technologies through the company's new VIMRx Genomics Inc. subsidiary (New York, N.Y.). During the five-year collaboration, VimRx Genomics will provide $30 million to the Columbia Genome...
BC Week In Review | Jan 4, 2000
Company News

Nexell other research news

Researchers at NEXL's Innovir Laboratories Inc. subsidiary (Wilmington, Del.) and colleagues published in Nature Biotechnology that oligos containing EGS, but not control sequences, were effective in specifically downregulating target mRNA transcripts. They suggested the technology...
BC Week In Review | Aug 23, 1999
Company News

Nexell, Ribozyme deal

RZYM acquired all ribozyme-related intellectual property from NEXL's Innovir Laboratories Inc. subsidiary (Wilmington, Del.), including ribozyme motifs, target validation, diagnostics, and oligonucleotide technology. RZYM said the acquisition relates to the closing of Innovir's ribozyme-based research...
BC Week In Review | Oct 19, 1998
Company News

Innovir cancer, infectious diseases news

Innovir, a subsidiary of VimRx Pharmaceuticals Inc. (VMRX, Wilmington, Delaware), said it will close its New York operations and relocate to VMRX's headquarters. In May, Innovir announced an operating expense reduction plan and began closing...
BC Week In Review | Jul 27, 1998
Company News

Innovir cancer, infectious diseases news

INVR was served with a complaint in the U.S. Bankruptcy Court for the Southern District of New York by the Trustee for the liquidation of the business of the now defunct investment firm A. R....
BC Week In Review | May 26, 1998
Company News

Innovir cancer, infectious diseases news

INVR, a subsidiary of VimRx Pharmaceuticals Inc. (VMRX, Wilmington, Del.) said its oligozyme development program will be refocused on functional ribozyme selection (FRS) and related technologies based on the company’s external guide sequence (EGS) technology....
BC Week In Review | May 11, 1998
Company News

Stressgen management update

(SSB SAB, below) StressGen Biotechnologies Corp. (TSE:SSB), Victoria, B.C.   Business: Cancer, Gene/Cell therapy, Infectious diseases   Hired: Paul Leibowitz as VP of corporate development, formerly SVP of Innovir Laboratories Inc.   Resigned: Vincent Salvatori,...
BC Week In Review | Mar 30, 1998
Company News

Innovir other research news

INVR, a subsidiary of VimRx Pharmaceuticals Inc. (VMRX, Wilmington, Del.), reported development of the FRS technology, which identifies sites in messenger RNA molecules that can be cleaved by a ribozyme or External Guide Sequence oligonucleotide....
Items per page:
1 - 10 of 22